<DOC>
	<DOCNO>NCT00006371</DOCNO>
	<brief_summary>RATIONALE : Androgens stimulate growth prostate cancer cell . Drugs aminoglutethimide ketoconazole may stop adrenal gland produce hormone . Combining hydrocortisone either aminoglutethimide ketoconazole may effective treatment prostate cancer . PURPOSE : Phase II trial study effectiveness combine hydrocortisone either aminoglutethimide ketoconazole treat patient localized stage IV prostate cancer .</brief_summary>
	<brief_title>A Phase II Trial Early Medical Adrenalectomy `` D0.5 '' Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine Prostate-Specific Antigen ( PSA ) response proportion duration response patient localized stage IV ( D0.5 ) adenocarcinoma prostate treat early medical adrenalectomy use hydrocortisone combine aminoglutethimide ketoconazole prior antiandrogen withdrawal . II . Compare incidence grade 3-4 toxicity regimens patient . III . Correlate adrenal androgen suppression response patient . OUTLINE : Patients stratify accord prior antiandrogen therapy ( yes v ) . Patients prior antiandrogen therapy begin study therapy appropriate antiandrogen withdrawal , without prior therapy begin study therapy immediately . Patients undergo medical adrenalectomy use hydrocortisone combine aminoglutethimide OR ketoconazole . Oral hydrocortisone administer twice daily . Oral aminoglutethimide administer twice daily 1 week 4 time daily subsequent week . Oral ketoconazole administer three time daily . Combination treatment continue absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Aminoglutethimide</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma prostate Stage IV ( D0.5 ; evidence disease CT bone scan testicular androgen ablation ) PSA progression testicular androgen ablation without antiandrogen therapy Progression define least 2 consecutive rise PSA level ( draw least 2 week apart ) great 50 % rise last nadir level ( arbitrary PSA least 2 ng/dL ) PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No medical condition would increase risk Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : See Disease Characteristics Greater 4 week since prior flutamide ( 6 week bicalutamide nilutamide ) No prior aminoglutethimide ketoconazole prostate cancer Continuation primary testicular androgen suppression ( i.e. , LHRH analog ) require Radiotherapy : Not specify Surgery : Not specify Other : No concurrent terfenadine , astemizole , cisapride , medicine know interact ketoconazole</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>